Literature DB >> 8751558

The prognostic significance of surgery, tumor size, malignancy grade, menopausal status, and DNA ploidy in endometrial stromal sarcoma.

R R Nordal1, G B Kristensen, J Kaern, A E Stenwig, E O Pettersen, C G Tropé.   

Abstract

To evaluate the prognostic significance of DNA ploidy in endometrial stromal sarcoma, the traditional clinical and histopathological prognostic variables and DNA ploidy in 48 patients with histologically verified endometrial stromal sarcoma were analyzed. Evaluable flow cytometric DNA histograms from paraffin-embedded tissue from the tumor were obtained in 47 patients. In univariate analysis, malignancy grade (P < 0.001), cellular atypia (P < 0.001), tumor diameter (P = 0.001), and mitotic count (P = 0.002) were highly significant. Also menopausal status (P = 0.011), FIGO stage (P = 0.035), and free resection margins at primary surgery (P = 0.026) obtained significance, while vessel invasion and age did not. DNA ploidy was not significant. In Cox multivariate analysis, free resection margins at primary surgery were found to be the most important prognostic factor (P < 0.001), followed by malignancy grade (P = 0.002), tumor diameter (P = 0.019), and menopausal status (P = 0.019). DNA ploidy did not obtain significance. Free resection margins at primary surgery, malignancy grade, tumor diameter, and menopausal status are important prognostic factors in endometrial stromal sarcoma.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8751558     DOI: 10.1006/gyno.1996.0224

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  9 in total

1.  Expression of metalloproteinases endometrial stromal sarcoma: immunohistochemical study using image analysis.

Authors:  P Liokumovich; I Goldberg; B Davidson; W H Gotlieb; T Zahavi; G Ben-Baruch; I Reder; J Kopolovic
Journal:  J Clin Pathol       Date:  1999-03       Impact factor: 3.411

Review 2.  High-grade undifferentiated sarcomas of the uterus: diagnosis, outcomes, and new treatment approaches.

Authors:  Charles-André Philip; Patricia Pautier; Florence Duffaud; Isabelle Ray-Coquard
Journal:  Curr Oncol Rep       Date:  2014-10       Impact factor: 5.075

3.  Endometrial stromal sarcoma. Is there a place for radiotherapy?

Authors:  Izaskun Valduvieco; Angeles Rovirosa; Lluis Colomo; Alex De San Juan; Jaume Pahisa; Albert Biete
Journal:  Clin Transl Oncol       Date:  2010-03       Impact factor: 3.405

4.  Primary characteristics and outcomes of newly diagnosed low-grade endometrial stromal sarcoma.

Authors:  Evan S Smith; Corinne Jansen; Kathryn M Miller; Sarah Chiang; Kaled M Alektiar; Martee L Hensley; Jennifer J Mueller; Nadeem R Abu-Rustum; Mario M Leitao
Journal:  Int J Gynecol Cancer       Date:  2022-07-04       Impact factor: 4.661

5.  [Uterine sarcoma treatment].

Authors:  G Köhler
Journal:  Pathologe       Date:  2009-07       Impact factor: 1.011

6.  Endometrial stromal sarcoma metastasis to the lumbar spine and sphenoid bone.

Authors:  Mary I Huang; Robert L Debernardo; Mark Rodgers; David J Hart
Journal:  Rare Tumors       Date:  2011-10-21

7.  Low-Grade Uterine Endometrial Stromal Sarcoma: Prognostic Analysis of Clinico-Pathological Characteristics, Surgical Management, and Adjuvant Treatments. Experience From Two Referral Centers.

Authors:  Fulvio Borella; Luca Bertero; Paola Cassoni; Elisa Piovano; Niccolò Gallio; Mario Preti; Stefano Cosma; Domenico Ferraioli; Luca Pace; Luca Mariani; Nicoletta Biglia; Chiara Benedetto
Journal:  Front Oncol       Date:  2022-06-30       Impact factor: 5.738

8.  Endometrial stromal tumors: immunohistochemical and molecular analysis of potential targets of tyrosine kinase inhibitors.

Authors:  Carmen Balañá; Enrique de Álava; Ruth Sardinha; Teresa Hernández; Susana Fraile; Francesc Tresserra; August Vidal; Maria Carmén Gómez; Aurora Astudillo; Nieves Hernández; Javier Saenz de Santamaría; Jaume Ordi; Luis Gonçalves; Rafael Ramos
Journal:  Clin Sarcoma Res       Date:  2013-03-07

9.  Endometrial stromal sarcoma: a population-based analysis.

Authors:  J K Chan; N M Kawar; J Y Shin; K Osann; L-M Chen; C B Powell; D S Kapp
Journal:  Br J Cancer       Date:  2008-09-23       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.